Hundred-and-seven subjects (71.8%; 64 CD, 37 UC, 6 IC) are currently treated with AZA (104) or 6MP (3). Maintenance of remission was achieved in 126 subjects (84.6%). Overall, AZA has been stopped in 44 and 6MP in 6 patients. Treatment was stopped because of side effects in 22 subjects (14.8%), including neutropenia, pancreatitis, hepatitis, nausea, fever and hypersensitivity reaction. All of them resolved after cessation of treatment and no serious event was reported. Other reasons to stop AZA/6MP were no/insufficient efficacy in maintaining remission (11), relapse of the disease (8) and patient's wish (9). Conclusion: Thiopurines are effective in maintaining remission in pediatric IBD patients and are well tolerated. No serious adverse event was reported and all were reversible. Our results are similar to those reported in the literature.
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The efficacy of infliximab in pediatric patients with steroid-dependent intestinal Behçet's disease: a single center experience in Japan S. Hagiwara *, M. Kubota, R. Nambu, S. Kagimoto. Saitama Children's Medical Center, Saitama, Japan Background: Infliximab (IFX) is a well-tolerated and effective therapy for intestinal Behçet's disease (BD) refractory to conventional medication in adult patients, but its efficacy in the treatment of pediatric intestinal BD is unknown. Methods: Pediatric patients with steroid-dependent intestinal BD treated with IFX at Saitama Children's Medical Center were retrospectively investigated. Results: A total of 3 patients (1 male, 2 females) aged 5 15 years with steroid-dependent intestinal BD were included in the study. All three patients had been treated with prednisolone, 5-aminosalicylic acid, colchicine, and azathioprine prior to IFX therapy. IFX (5 mg/kg) was infused at weeks 0, 2, and 6 for remission induction in all patients. Two patients were then treated with IFX every 8 weeks as scheduled for maintenance therapy, and the other patient was treated with IFX on demand. The dose of IFX had to be increased to 10 mg/kg for secondary failure in all patients. One patient stopped taking IFX after developing neuro-BD, despite an improvement in intestinal symptoms. One patient was refractory to the increased dose of IFX, and was switched Downloaded from https://academic.oup.com/ecco-jcc/article-abstract/8/Supplement_2/S428/339809 by guest on 04 March 2019
